Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

A. J. van der Wekken*, R. Pelgrim, N. 't Hart, N. Werner, M. F. Mastik, L. Hendriks, E. H. F. M. van der Heijden, M. Looijen-Salamon, A. J. de langen, J. Staal-van den Brekel, S. Riemersma, B. E. van den Borne, E. J. M. Speel, A-M. C. Dingemans, T. J. N. Hiltermann, A. van den Berg, W. Timens, E. Schuuring, H. J. M. Groen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Downloads (Pure)
Original languageEnglish
Pages (from-to)4251-4258
Number of pages8
JournalClinical Cancer Research
Volume23
Issue number15
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • IN-SITU HYBRIDIZATION
  • CRIZOTINIB THERAPY
  • GENE REARRANGEMENT
  • COPY NUMBER
  • IMMUNOHISTOCHEMISTRY
  • ADENOCARCINOMA
  • IDENTIFICATION
  • CARCINOMAS
  • ONCOLOGY
  • FUSION

Cite this